Therapeutic delivery of cyclin-A2 via recombinant adeno-associated virus serotype 9 restarts the myocardial cell cycle: An in vitro study

Ma,Xiang; Zhao,Aichao; Yao,Yongzhao; Cao,Wen; Karmacharya,Ujit; Liu,Fen; Chen,Bangdang; Baozhu,Wang; Ying,Huang; Ma,Yitong

doi:10.3892/mmr.2015.3147

May-2015 Volume 11 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 11 Issue 5

Full Size Image

Article

Therapeutic delivery of cyclin-A2 via recombinant adeno-associated virus serotype 9 restarts the myocardial cell cycle: An in vitro study

Authors:
- Xiang Ma
- Aichao Zhao
- Yongzhao Yao
- Wen Cao
- Ujit Karmacharya
- Fen Liu
- Bangdang Chen
- Wang Baozhu
- Huang Ying
- Yitong Ma
View Affiliations / Copyright

Affiliations: Department of Cardiovascular Medicine, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Pages: 3652-3658
|
Published online on: January 7, 2015

https://doi.org/10.3892/mmr.2015.3147
Expand metrics +

Abstract

Cyclin‑A2, which is downregulated following birth, has previously been established as a key regulator of the cell cycle. The present study aimed to detect the effects of cyclin‑A2 on myocardial cells by using recombinant adeno‑associated virus 9 (rAAV9). Sixty mice were selected and randomly divided into two groups (n=30). The control group were injected with saline and the experimental group were transfected with the rAAV9‑cyclinA2‑CMV vector by intravenous injection into the tail vein. Tissues were harvested at two and four weeks following injection. Cyclin‑A2 expression levels and localization were evaluated using western blot and immunohistochemical analyses. DNA synthesis and mitosis in the myocardium were confirmed by analyzing proliferating cell nuclear antigen (PCNA) and phospho‑histone H3 (H3P) expression levels. Expression of Cyclin‑A2 in the myocardium commenced two weeks following tail vein injection in the cyclin‑A2‑treated group, while no expression was observed in the control group. Four weeks following injection, expression levels of cyclin‑A2 were higher than those observed at two weeks following injection into the myocardium (two weeks: 0.146±0.013 vs. 27.1±3.33%, P<0.001; four weeks: 0.142±0.107 vs. 74.4±3.36%, P<0.001). PCNA displayed increased expression levels in the cyclin‑A2‑treated group (two weeks: 13.1±0.54 vs. 65.8±3.44%, P<0.001; four weeks: 13.2±0.55 vs. 71.2±1.58%, P<0.001); however, no change was observed in those of the control group. By contrast, no significant difference was observed in mitosis marker H3P expression levels between the two groups. Immunohistochemical analysis of cyclin‑A2 indicated cytoplasmic, but not nuclear, localization. cyclin‑A2 and PCNA expression levels in the liver, lung and kidney showed no significant difference between the two groups (P>0.05). It was therefore concluded that the delivery of cyclin‑A2 via rAAV9 to the mouse myocardium restarted the myocardial cell cycle, thereby establishing steady and specific expression in the myocardium. Furthermore, the effect of Cyclin‑A2 on the myocardium may provide a novel method for achieving cardiac regeneration following cardiac injury.

View Figures

View References

1	Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326. 2002. View Article : Google Scholar : PubMed/NCBI
2	Pagano M1, Pepperkok R, Verde F, Ansorge W and Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J. 11:961–971. 1992.PubMed/NCBI
3	Yoshizumi M, Lee WS, Hsieh CM, Tsai JC, Li J, Perrella MA, Patterson C, Endege WO, Schlegel R and Lee ME: Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 95:2275–2280. 1995. View Article : Google Scholar : PubMed/NCBI
4	Li Y, Hu S, Ma G, Yao Y, Yan G, Chen J, Li Y and Zhang Z: Acute myocardial infarction induced functional cardiomyocytes to re-enter cell cycle. Am J Transl Res. 5:327–335. 2013.
5	Mingozzi F and High KA: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 12:341–355. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wright MJ, Wightman LM, Lilley C, de Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS and Marber MS: In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol. 96:227–236. 2001. View Article : Google Scholar : PubMed/NCBI
7	Flotte TR: Recent developments in recombinant AAV-mediated gene therapy for lung diseases (Review). Curr Gene Ther. 5:361–366. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sands MS: AAV-mediated liver-directed gene therapy. Methods Mol Biol. 807:141–157. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mandel RJ: CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease. Curr Opin Mol Ther. 12:240–247. 2010.PubMed/NCBI
10	Rolling F: Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives (Review). Gene Ther. 11(Suppl 1): S26–S32. 2011. View Article : Google Scholar
11	Pacak CA and Byrne BJ: AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities (Review). Mol Ther. 19:1582–1590. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM and Sweeney HL: Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 19:1359–1368. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bostick B, Ghosh A, Yue Y, Long C and Duan D: Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14:1605–1609. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zincarelli C, Soltys S, Rengo G and Rabinowitz JE: Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 16:1073–1080. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fang H, Lai NC, Gao MH, Miyanohara A, Roth DM, Tang T and Hammond HK: Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum Gene Ther Methods. 23:234–241. 2012. View Article : Google Scholar : PubMed/NCBI
16	Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA and Nakai H: Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 14:45–53. 2006. View Article : Google Scholar : PubMed/NCBI
17	Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Hsu VM, Cohen JE and Chaudhry HW: Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation. 114(1 Suppl): I206–I213. 2006. View Article : Google Scholar : PubMed/NCBI
18	Cheng RK, Asai T, Tang H, Dashoush NH, Kara RJ, Costa KD, Naka Y, Wu EX, Wolgemuth DJ and Chaudhry HW: Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res. 100:1741–1748. 2007. View Article : Google Scholar : PubMed/NCBI
19	Svensson EC, Marshall DJ, Woodard K, Lin H, Jiang F, Chu L and Leiden JM: Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinat adeno-associated virus vectors. Circulation. 99:201–205. 1999. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Song Y, Ren J and Qu X: Knocking-down Cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin. PLoS One. 4:e66652009. View Article : Google Scholar : PubMed/NCBI
21	Jackman M, Kubota Y, den Elzen N, Hagting A and Pines J: Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell. 13:1030–1045. 2002. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Therapeutic delivery of cyclin-A2 via recombinant adeno-associated virus serotype 9 restarts the myocardial cell cycle: An in vitro study

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles